Zingrillo Matteo, Modoni Sergio, Conte Matteo, Frusciante Vincenzo, Trischitta Vincenzo
Unità di Endocrinologia, Scientific Institute Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
J Nucl Med. 2003 Feb;44(2):207-10.
Therapeutic options for toxic thyroid nodules (TTNs) are surgery, radioiodine (RAI), and percutaneous ethanol injection (PEI). Surgery is generally considered for TTNs larger than 4 cm. However, some patients may be at high surgical risk. The purpose of the study was to evaluate the efficacy of 2 nonsurgical modalities for these TTNs.
Twenty-two patients with TTNs larger than 4 cm were randomly assigned to 2 different treatments: to 11 (subgroup A), RAI was administered at a dose of 12,580 kBq/mL of nodular volume (NV) and was corrected for 100% 24-h (131)I uptake (RAIU); to 11 (subgroup B), 2-4 PEI sessions (ethanol injected = 30% NV) preceded 2 mo of 24-h RAIU and RAI dosing. Inclusion criteria were clinical and biochemical hyperthyroidism; a single palpable, hot nodule at (99m)Tc scintigraphy; and high surgical risk or refusal to have surgery. Patients gave informed consent. Local symptoms were evaluated by a previously validated score (symptom score, or SYS).
Both treatments were well tolerated. Subgroup B showed a significant reduction of NV 2 mo after PEI: 33.6 +/- 18.5 versus 60.8 +/- 29.5 mL. Their 24-h RAIU was similar to that of subgroup A: 53.9 +/- 13.9 versus 61.8% +/- 11.0%. Consequently, the administered RAI dose was significantly lower for subgroup B (730 +/- 245 MBq) than for subgroup A (1,048 +/- 392 MBq). Twelve months after RAI, subgroup B had a higher NV reduction and a lower SYS than did subgroup A. In subgroup A, 1 patient was subclinically hyperthyroid, 2 showed a slight increase of thyroid-stimulating hormone, and 1 was clinically hypothyroid. In subgroup B, 1 patient had a slight increase of thyroid-stimulating hormone.
We demonstrated that RAI, alone or with PEI, can be considered a valid alternative for TTNs larger than 4 cm when surgery is either refused or contraindicated. PEI plus RAI can be considered when marked shrinkage of a nodule is required or when reduction of the RAI dose can prevent hospitalization.
毒性甲状腺结节(TTN)的治疗选择包括手术、放射性碘(RAI)和经皮乙醇注射(PEI)。对于直径大于4cm的TTN,通常考虑手术治疗。然而,一些患者手术风险可能较高。本研究的目的是评估这两种非手术治疗方式对这些TTN的疗效。
22例直径大于4cm的TTN患者被随机分为两种不同治疗组:11例(A亚组),给予RAI,剂量为每毫升结节体积(NV)12580kBq,并根据24小时100%的碘-131摄取率(RAIU)进行校正;11例(B亚组),在进行2个月的24小时RAIU和RAI给药前,先进行2-4次PEI治疗(乙醇注射量=30%NV)。纳入标准为临床和生化甲亢;在锝-99m闪烁扫描中可触及单个热结节;手术风险高或拒绝手术。患者均签署知情同意书。通过先前验证的评分(症状评分,或SYS)评估局部症状。
两种治疗耐受性均良好。B亚组在PEI治疗2个月后NV显著降低:33.6±18.5ml对比60.8±29.5ml。其24小时RAIU与A亚组相似:53.9±13.9对比61.8%±11.0%。因此,B亚组给予的RAI剂量(730±245MBq)显著低于A亚组(1048±392MBq)。RAI治疗12个月后,B亚组的NV降低幅度更大,SYS更低。在A亚组中,1例患者为亚临床甲亢,2例促甲状腺激素略有升高,1例为临床甲减。在B亚组中,1例患者促甲状腺激素略有升高。
我们证明,当手术被拒绝或禁忌时,单独使用RAI或联合PEI可被视为直径大于4cm的TTN的有效替代治疗方法。当需要结节明显缩小或降低RAI剂量可避免住院时,可考虑PEI联合RAI治疗。